1. Treatment with dasatinib and blinatumomab was associated with high incidence of molecular response in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL).
2. Treatment with dasatinib and blinatumomab for patients with Ph-positive ALL was associated with a high incidence of survival.
Evidence Rating Level: 2 (Good)
Study Rundown: Prognosis for...